MedTrace Logo

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

NCT02133781 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2018-06-06

Study results available
· View outcomes & findings →

Summary

This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 2009-2010 influenza vaccines in children and adults.

Conditions

Interventions

BIOLOGICAL

Fluzone® 2009-2010 Formula

This vaccine is given intramuscularly

BIOLOGICAL

FluMist® 2009-2010 Formula

This vaccine is given intranasally

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia L Dekker, MD · Stanford University

  • Harry B Greenberg, MD · Stanford University

  • Xiaosong He, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133781 on ClinicalTrials.gov